Subtopic Deep Dive

Primary Graft Dysfunction in Lung Transplantation
Research Guide

What is Primary Graft Dysfunction in Lung Transplantation?

Primary graft dysfunction (PGD) is a severe form of ischemia-reperfusion injury occurring within 72 hours after lung transplantation, characterized by nonspecific alveolar damage, lung edema, and hypoxemia.

PGD represents the most severe early complication post-lung transplant, often leading to primary graft failure (de Perrot et al., 2003). Incidence and severity grading are tracked in international registries (Chambers et al., 2017). Research spans over 1,000 papers, with key studies on pathophysiology and donor management cited over 900 times.

15
Curated Papers
3
Key Challenges

Why It Matters

PGD causes 20-30% of early post-transplant mortality, driving needs for better donor lung preservation (de Perrot et al., 2003; Chambers et al., 2017). Normothermic ex vivo lung perfusion reduces PGD risk in high-risk donors, matching conventional lung outcomes (Cypel et al., 2011). Guidelines integrate PGD prevention into donor selection and intraoperative strategies (Costanzo et al., 2010).

Key Research Challenges

Ischemia-Reperfusion Mechanisms

PGD arises from endothelial injury and inflammatory cascades during reperfusion (de Perrot et al., 2003). Identifying precise molecular triggers remains elusive despite animal models. Over 900 citations highlight persistent gaps in translation to humans.

Risk Factor Prediction

Donor factors like ischemic time correlate with PGD incidence per registry data (Chambers et al., 2017). Predictive models lack precision for individual cases. Biomarker discovery is limited by heterogeneous cohorts.

Preventive Interventions

Ex vivo perfusion shows promise but requires optimization for widespread adoption (Cypel et al., 2011). Intraoperative strategies need randomized validation. Long-term outcome impacts are understudied beyond 30 days.

Essential Papers

1.

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

Maria Rosa Costanzo, Maria Rosa Costanzo, Anne I. Dipchand et al. · 2010 · The Journal of Heart and Lung Transplantation · 1.6K citations

2.

The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update

Mandeep R. Mehra, Charles E. Canter, Margaret M. Hannan et al. · 2016 · The Journal of Heart and Lung Transplantation · 1.4K citations

3.

REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY

Thomas E. Starzl, K. A. Porter, Shunzaburo Iwatsuki et al. · 1984 · The Lancet · 1.3K citations

4.

Chimerism of the Transplanted Heart

Federico Quaini, Konrad Urbanek, Antonio Paolo Beltrami et al. · 2002 · New England Journal of Medicine · 1.3K citations

Our results show a high level of cardiac chimerism caused by the migration of primitive cells from the recipient to the grafted heart. Putative stem cells and progenitor cells were identified in co...

5.

Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria

Marc Estenne, J.R. Maurer, Annette Boehler et al. · 2002 · The Journal of Heart and Lung Transplantation · 1.3K citations

6.

Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients

Howard J. Eisen, E. Murat Tuzcu, Richard Dorent et al. · 2003 · New England Journal of Medicine · 1.2K citations

Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.

7.

Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation

Marcelo Cypel, Jonathan Yeung, Mingyao Liu et al. · 2011 · New England Journal of Medicine · 1.1K citations

Transplantation of high-risk donor lungs that were physiologically stable during 4 hours of ex vivo perfusion led to results similar to those obtained with conventionally selected lungs. (Funded by...

Reading Guide

Foundational Papers

Start with de Perrot et al. (2003) for PGD pathophysiology definition; Costanzo et al. (2010) for guidelines integrating PGD prevention; Chambers et al. (2017) for incidence baselines.

Recent Advances

Cypel et al. (2011) demonstrates ex vivo perfusion efficacy; Chambers et al. (2017) updates registry data on ischemic time impacts.

Core Methods

Core techniques: ISHLT grading (Chambers et al., 2017), normothermic perfusion (Cypel et al., 2011), reperfusion injury models (de Perrot et al., 2003).

How PapersFlow Helps You Research Primary Graft Dysfunction in Lung Transplantation

Discover & Search

Research Agent uses searchPapers to retrieve 1,000+ PGD papers via OpenAlex, then citationGraph on de Perrot et al. (2003) reveals 962 downstream studies on ischemia-reperfusion. findSimilarPapers expands to ex vivo perfusion works like Cypel et al. (2011); exaSearch queries 'primary graft dysfunction biomarkers lung transplant' for latest preprints.

Analyze & Verify

Analysis Agent applies readPaperContent to extract PGD grading from Chambers et al. (2017), then verifyResponse with CoVe cross-checks incidence claims against Costanzo et al. (2010). runPythonAnalysis processes registry data for survival curves (NumPy/pandas); GRADE grading scores evidence strength for ex vivo perfusion interventions.

Synthesize & Write

Synthesis Agent detects gaps in PGD biomarker validation via contradiction flagging across de Perrot (2003) and Cypel (2011). Writing Agent uses latexEditText for methods sections, latexSyncCitations for 50+ refs, latexCompile for full review; exportMermaid diagrams ischemia-reperfusion pathways.

Use Cases

"Analyze survival rates in PGD grade 3 from ISHLT registry data"

Research Agent → searchPapers('PGD grade 3 survival') → Analysis Agent → readPaperContent(Chambers 2017) → runPythonAnalysis (pandas survival curves, matplotlib plots) → statistical p-values and Kaplan-Meier outputs.

"Draft LaTeX review on ex vivo lung perfusion for PGD prevention"

Synthesis Agent → gap detection (Cypel 2011 vs de Perrot 2003) → Writing Agent → latexGenerateFigure (perfusion diagram) → latexSyncCitations → latexCompile → PDF with synced refs and figures.

"Find code for PGD risk prediction models from papers"

Research Agent → searchPapers('PGD prediction model') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → executable Python scripts for logistic regression on donor factors.

Automated Workflows

Deep Research workflow synthesizes 50+ PGD papers into structured report: searchPapers → citationGraph → GRADE all evidence → exportCsv stats. DeepScan applies 7-step CoVe to verify PGD incidence claims from Chambers (2017) against registries. Theorizer generates hypotheses on PGD biomarkers from de Perrot (2003) pathways.

Frequently Asked Questions

What defines primary graft dysfunction?

PGD is graded 0-3 based on PaO2/FiO2 ratio and radiographic infiltrates within 72 hours post-transplant (de Perrot et al., 2003; Chambers et al., 2017).

What are main methods to study PGD?

Methods include registry analyses (Chambers et al., 2017), ex vivo perfusion trials (Cypel et al., 2011), and ischemia-reperfusion models (de Perrot et al., 2003).

What are key papers on PGD?

de Perrot et al. (2003, 962 citations) defines mechanisms; Cypel et al. (2011, 1067 citations) validates ex vivo perfusion; Chambers et al. (2017, 1029 citations) reports incidence.

What open problems exist in PGD research?

Challenges include biomarker validation, personalized risk models, and scaling preventive perfusion beyond trials (de Perrot et al., 2003; Cypel et al., 2011).

Research Transplantation: Methods and Outcomes with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Primary Graft Dysfunction in Lung Transplantation with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers